Hussman Strategic Advisors’s Standard BioTools LAB Stock Holding History

Hussman Strategic Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-144,000	Closed	-$887K	–	338
2021 Q2	$887K	Hold	144,000	–	–	0.18%	197
2021 Q1	$651K	Sell	144,000 -60,000	-29%	-$330K	0.13%	230
2020 Q4	$1.22M	Hold	204,000	–	–	0.32%	125
2020 Q3	$1.52M	Buy	+204,000	New	+$1.41M	0.4%	101

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hussman Strategic Advisors's LAB Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of Standard BioTools (LAB) in Q3 2021, closing a stake of 144,000 shares — an estimated $887K sold.

Hussman Strategic Advisors first reported a position in LAB in Q3 2020 and held it in 4 quarters. The position peaked at $1.52M in Q3 2020. 119 funds tracked by Wall St. Rank hold LAB as of Q3 2021.

Hussman Strategic Advisors reported no remaining Standard BioTools position as of Q3 2021 after selling out during the quarter.
Hussman Strategic Advisors sold 144,000 Standard BioTools shares in Q3 2021, an estimated $887K.
Hussman Strategic Advisors first reported a position in Standard BioTools in Q3 2020 and held it in 4 quarters.
Hussman Strategic Advisors's Standard BioTools position peaked at $1.52M in Q3 2020.
119 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.